Keeping Current

Biosimilars in Multiple Sclerosis: Entering a New Era of Biologic Therapy

Informações:

Synopsis

Did you know what the inherent variability of all biologics and what degree of variation are acceptable by regulatory bodies?  Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/989395?src=mkm_podcast_addon_989395